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The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two
main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory amino acid transporter (VIAAT) and are both
present in neurons during postnatal development. We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA
in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.
We found that glycine is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial
transporter GlyT1. However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode,
which gives it an advantage in maintaining the high cytosolic glycine concentration required for efficient vesicular loading by VIAAT. The
vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into
the secretory cell and competes for uptake by VIAAT. Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species
lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes
GABA transmission in the worm confers glycine specificity. Together, these results suggest that an increased cytosolic availability of
glycine in VIAAT-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.
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Introduction
Glycine and GABA are the major fast inhibitory neurotransmit-
ters released at central synapses but, in contrast to the widespread
usage of GABA, glycine transmission is restricted to the spinal
cord, hindbrain, and retina. In these structures, glycine signaling
is not segregated from, but intermingles with GABA signaling at
both presynaptic (Burger et al., 1991; Christensen et al., 1991;
Todd et al., 1996; Dumba et al., 1998) and postsynaptic levels
(Triller et al., 1987; Bohlhalter et al., 1994). Although both amino
acids can be released separately or together (Jonas et al., 1998;
O’Brien and Berger, 1999), the mechanisms that specify their
relative contribution in vesicles are not fully understood. Glycine
and GABA share the same vesicular transporter, named vesicular
inhibitory amino acid transporter (VIAAT) or vesicular GABA
transporter (VGAT) (McIntire et al., 1997; Sagné et al., 1997;
Chaudhry et al., 1998; Dumoulin et al., 1999; Wojcik et al., 2006),
but, in contrast to GABA, glycine uptake by recombinant VIAAT
has not been detected (G. C. Bellenchi and B. Gasnier, unpub-
lished data). In addition, it is not known how glycine, with an
estimated IC50 value of 27 mM (McIntire et al., 1997; Bedet et
al., 2000), can effectively compete with GABA for uptake by
VIAAT.
To demonstrate glycine uptake by VIAAT, we expressed the
vesicular transporter in the neuroendocrine serotoninergic cell
line BON and used a sniffer patch-clamp technique to detect
vesicular release of glycine. A similar approach has been previ-
ously used to show that expression of the vesicular glutamate
transporter VGLUT1 is sufficient to induce glutamate exocytosis
(Takamori et al., 2000). However, in the case of glycine, we sus-
pected that expression of the vesicular transporter VIAAT would
not be sufficient to induce glycine exocytosis, despite the ubiquity
of this amino acid, because genetic disruption of GlyT2 in mice
(Gomeza et al., 2003) and humans (Eulenburg et al., 2006; Rees et
al., 2006) reduces glycinergic transmission and causes hyperek-
plexia. Therefore, the primary role of GlyT2 may be to stockpile
very large amounts of glycine in nerve terminals to promote sig-
nificant VIAAT-mediated vesicular filling.
This hypothesis, in which plasmalemmal uptake replaces bio-
synthetic enzymes for the supply of transmitter to the synaptic
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vesicle and therefore determines the presynaptic phenotype, im-
plies that under physiological condition, GlyT2 accumulates su-
pramillimolar levels of glycine from a low micromolar extracel-
lular source. For this to occur, GlyT2 must therefore compete
successfully with the glial recapture of glycine by the transporter
GlyT1, with which it shares a common extracellular space. To
investigate the functional coupling of plasmalemmal and vesicu-
lar glycine uptake, we compared the release of glycine from
VIAAT-containing vesicles when GlyT1 is substituted for GlyT2
in the BON cell model. Then, we examined alterations in vesicu-
lar glycine content introduced by GABA competition for VIAAT.
We were able to clearly differentiate the release of glycine and
GABA from single vesicles by using specific ligand-gated chan-
nels with different ionic permeabilities. Finally, we determined
whether a change in the substrate specificity of the vesicular
transporter was required for the emergence of glycine transmis-
sion in vertebrates by comparing VIAAT with an invertebrate
ortholog.
Materials and Methods
Plasmids and molecular biology. cDNA of the human glycine receptor-1
(GlyR-1; a gift from H. Betz, Max-Planck Institute for Brain Research,
Frankfurt, Germany) was subcloned into a pIRES2-EGFP vector (Clon-
tech, Cambridge, UK), whereas cDNAs coding for the C. elegans EXP-1A
(a gift from E. M. Jorgensen, University of Utah, UT) was subcloned in
the p3pA plasmid vector (Roux and Supplisson, 2000) and transfected
into human embryonic kidney 293 (HEK293) cells. Rat GlyT1b (a gift
from K. Smith, Synaptic Pharmaceutical, Paramus, NJ), rat GlyT2a (a gift
from B. López-Corcuera and C. Aragón, Universidad Autónoma de Ma-
drid, Madrid, Spain), and rat GABA transporter subtype 1 (GAT1; a gift
from B. Kanner, Hebrew University, Jerusalem, Israel) were subcloned in
the p3pA plasmid vector for transfection into BON cells (a gift from
C. M. Townsend, University of Texas Medical Branch, Galveston, TX)
along with a cDNA coding for EGFP for identification of transfected cells.
Rat VIAAT cDNA (a gift from B. Giros, Inserm U513, Créteil, France)
was subcloned into pcDNA3 and stably expressed in BON cells as de-
scribed previously by Gras et al. (2002). Two independent stable trans-
fectants were used throughout this study. C. elegans unc-47 cDNA (a gift
from E. M. Jorgensen) was subcloned into pIRES2-EGFP, and the G462R
mutation was introduced by Quikchange site-directed mutagenesis
(Stratagene, La Jolla, CA) and verified by sequencing.
Cell culture and transfection. HEK293 cells were grown in DMEM sup-
plemented with 10% fetal calf serum (Sigma, St. Louis, MO), 100 IU/ml
penicillin, and 100 g/ml streptomycin in a 5% CO2/air atmosphere.
BON cells were cultured as indicated in Gras et al. (2002). HEK293 and
BON cells were cultured on glass coverslips (Marienfeld, Germany) and
transient transfections were performed with 1–3 g of cDNAs using
standard protocols provided with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) or GeneJammer (Stratagene) transfection kits. Coexpres-
sion of GlyR and EXP1 in HEK293 cells was achieved with a 1:5 DNA
ratio. After transfection, BON cells were maintained in nominally
glycine-free media (BHK-21 media, without serum) and glycine and/or
GABA (300 M unless otherwise indicated) were added to the media
12–24 h before experiments. The expression of GlyT1 and GlyT2 at the
membrane surface of BON cells was confirmed by confocal microscopy
and by recording the whole cell transporter current evoked by glycine
(300 M) at 70 mV (data not shown). The average amplitudes of the
glycine-evoked currents were 1.42  0.5 pA/pF (n  4) for GlyT1 and
0.74  0.5 pA/pF (n  4) for GlyT2. Cell culture reagents were supplied
by Invitrogen or PAA Laboratories (Linz, Austria).
Sniffer-patch electrophysiology. Whole-cell patch-clamp recordings
from EGFP- expressing HEK293 cells were performed using an Axopatch
200A amplifier (Molecular Devices, Menlo Park, CA) and borosilicate
glass pipettes with a typical resistance of 4 – 6 M, coated with dental wax
and filled with either of the following solutions (in mM): 155
K-gluconate, 4 KCl, 10 HEPES, 0.1 EGTA, 5 ATP-Mg, pH 7.3 (see Figs.
1–3); or 135 K-gluconate, 4 KCl, 20 HEPES, 20 BAPTA, 5 ATP-Mg, pH
7.3 (see Figs. 4 –7). HEK293 cells were held at 45 mV and lifted off the
coverslip and tested for their receptor expression by rapid application of
glycine or GABA (200 M) using an automated multibarrel perfusion
system (SF-77B; Warner Instrument, Hamden, CT). Only HEK293 cells
with current amplitudes of 1–3 nA for GlyR and 0.4 –2 nA for EXP1 were
used in experiments. Patch-clamped HEK293 cells were gently pressed
onto the surface of transfected BON cells expressing EGFP using a piezzo
micromanipulator (Polytec PI, Pantin, France). Acetylcholine (ACh)
(100 M) was applied to trigger exocytotic release of glycine or GABA
from BON cells. Currents were filtered at 1–2 kHz and acquired at 10 –20
kHz using Digidata 1200 (Molecular Devices) and Clampex acquisition
software (Pclamp 8; Molecular Devices). Between trials, the currents
evoked by glycine and GABA, along with the cell capacitance and series
resistance, were continuously monitored to verify the stability of the
HEK cell. Because the release rate decreases to near zero during pro-
longed ACh (100 M) applications (1 min; data not shown), ACh was
applied up to 10 times (typically six) to each BON cell every 3– 4 min.
BON cells with a mean release rate lower than 2 events/min were dis-
carded for further analysis to ensure a representative sampling of the
vesicles population for different trials. Inhibitory transmitter release rate
varied greatly from cell to cell. The cumulative release rates are normal-
ized per minute of ACh application and averaged over multiple BON
cells. When direct comparison of conditions were necessary, such as the
experiments presented in Figure 3 B, D, experiments were performed
over a few days from a more homogenous subset of BON cells cultured in
comparable conditions.
Experiments were performed at room temperature. ORG25543 was a
generous gift from H. Sundaram and D. Hill (Organon, Newhouse, UK).
NNC-711 was supplied by Tocris Bioscience (Bristol, UK), and all other
chemicals were obtained from Sigma.
Ca2 imaging. Before the experiments, BON cells were incubated for
20 min with 5 M Ca 2 dye Fluo4/AM (Invitrogen). Images of epifluo-
rescence were acquired at 1 Hz using a CoolSNAP-ES CCD camera
(Roper Scientific, Tucson, AZ). We measured the mean intensity of flu-
orescence in the cell body using Metaview software (Universal Imaging,
West Chester, PA) and calculated the relative fluorescence change as
follows: F/F  (F  F0)/F0, where F0 is the average basal fluorescence
recorded before ACh application.
Analysis. Events were detected by the threshold method (10 and 5
pA for glycine and GABA events, respectively) using ClampFit (Pclamp
8-9; Molecular Devices). Glycine and GABA corelease was identified as
outward followed by inward current occurring 	100 ms apart (see Fig.
5D). Data are expressed as means  SEM with n, the number of repeats
given in parentheses. Significance ( p 	 0.05) was tested using an F test.
Concentration-response curves of the current mediated by the activa-
tion of glycine or GABA receptors were fitted using the Hill equation:
I 
Imax
1   EC50
agonist
h ,
where Imax is the maximal current elicited by substrate, h is the Hill
coefficient, and EC50 is the concentration that activates 50% of Imax.
The cumulative distribution function (cdf) of the peak event ampli-
tudes were fitted as the sum of two log-normal distributions:
cdf 
n1
2 1  erf lnx  112   n22 1  erf lnx  222 ,
where x is the absolute event amplitude, ni is the number of events, and i
and i are the mean and SD of the logarithm of the amplitude,
respectively.
Results
Plasmalemmal uptake of glycine promotes its
vesicular release
Patch-clamped HEK293 cells expressing homomeric 1-glycine
receptors (GlyR) were pressed against neuroendocrine BON cells
(Parekh et al., 1994) expressing VIAAT and GlyT2 (Fig. 1A).
Application of ACh, which stimulates secretion from BON cells
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(Parekh et al., 1994; Takamori et al.,
2000), triggered in the BON cells intracel-
lular Ca 2 oscillations that were sensitive
to the non-M2 muscarinic receptor antag-
onist 4-DAMP (Fig. 1B) and evoked a
burst of transient outward currents in the
HEK cell (Fig. 1C). In contrast, transient
currents were not detected in HEK cells
that were not pressed onto BON cells (data
not shown) or when HEK cells were
pressed on naive (VIAAT-negative) or
GlyT2-only-expressing BON cells (Fig.
1D). No or few events were detected with
VIAAT-only-expressing BON cells (Fig.
1D) or if BON/VIAATGlyT2 cells were
incubated with ORG25543 (data not
shown), a GlyT2-specific inhibitor (Roux
and Supplisson, 2000; Caulfield et al.,
2001). Application of strychnine, a glycine
receptor antagonist, blocked the transient
currents (Fig. 1E), indicating that they
correspond to the release of glycine from
the BON cells. These GlyR-mediated cur-
rents (Fig. 2A–B) had fast kinetics (10 –
90% rise time, 3.7  0.1 ms and 10 –90%
decay time, 14.8  0.2 ms; n  4199) (Fig.
2C) and occurred at a mean rate of 15.4 
1.2 events/min (n  41) of ACh applica-
tion with a first latency of 16  0.9 s (n 
41) (Fig. 2D). They appeared monophasic
and independent of each other, without
evidence for multivesicular release, de-
spite having high current-amplitude vari-
ability during each trial (coefficient of
variation 1). The cumulative probability
curve of the peak-current amplitudes was
bimodal and well described by the sum of
two log-normal distributions (Fig. 2E), in
agreement with the existence of several
populations of secretory vesicles in the
BON cell line (Parekh et al., 1994).
GlyT2 supports glycine release more
efficiently than GlyT1
We compared the peak amplitude and the
frequency of the release events detected
from BON/VIAAT cells coexpressing ei-
ther GlyT2 or GlyT1. When these BON
cells were incubated for 12–24 h in a me-
dium containing 3 M extracellular gly-
cine ([Gly]e), a concentration within the
range measured in the CSF (Jones et al.,
2006), glycine release was detected from
BON/VIAATGlyT1 (Fig. 3A) with uni-
tary events of similar amplitudes than
those observed with GlyT2-expressing
cells (Fig. 3A–B), albeit at half the fre-
quency [7.0  0.9 events/min (n  8) and
14.6  3.1 events/min (n  8), respec-
tively, p 	 0.05]. This difference in fre-
quency was not observed when BON cells
were incubated overnight with 300 M
glycine [15.6  2.9 events/min (n  8) for
Figure 2. Characteristics of the glycine events. A, Left, A current trace illustrating the broad range of glycine-events amplitudes.
Right, Expanded view of 153 successive exocytotic events and their average (red trace) recorded during eight ACh applications to
a single BON/VIAATGlyT2 cell. B, Small and large glycine-events (left) have comparable activation kinetics when normalized
(right). C, Distribution probabilities of the 10 –90% rise time (left) and 10 –90% decay time (right) of glycine events (n  4199).
The cumulative probabilities are shown in red. D, Histograms of number (left) and first-latency (right) of the glycine-events
recorded during each ACh application (n  41). E, Normalized cumulative distribution of glycine-event peak-amplitudes recorded
from five BON/VIAATGlyT2 cells (closed circles; 44 ACh applications, 688 events) incubated overnight in 300 M glycine. The
solid line corresponds to the fit of the data with the sum of two log-normal cumulative distribution functions (see Materials and
Methods). The dashed lines represent the individual distributions with n1  5.7, 1  3.4, 1  0.49 (red line) and n2  9.3, 2
 5.1, 2  1.0 (blue line).
Figure 1. VIAAT and GlyT2 coexpression promotes quantal glycine release. A, Schematic representation of the BON/HEK293
model. The micrograph is an overlay of phase contrast and green fluorescence images that shows two BON cells and a patch-
clamped HEK293 cell expressing EGFP pressed on top of one of the BON cells. B, Left, Time course of Fluo4/AM fluorescence change
in five representative BON/VIAAT cells evoked by the application of acetylcholine (bar, 100 M). Right, Application of 4-DAMP (0.1
M, red bar), a non-M2 muscarinic receptor antagonist, blocks the Ca 2 oscillations evoked by acetylcholine in five representative
BON/VIAAT cells. C, A representative current trace recorded with a HEK/GlyR cell during ACh stimulation (bar, 100 M) of a
BON/VIAATGlyT2 cells after overnight incubation with glycine-containing media (300 M). Transient currents were recorded
from 114/301 BON/VIAATGlyT2 cells tested. D, No events were detected from naive BON cells (top trace, 18/18 cells) or from
BON/GlyT2 cells (middle trace, 31/31 cells). No (in 60/71 cells) or small, low frequency transient currents (in 11/71 cells) were
detected from BON/VIAAT cells (bottom trace). E, Transient currents recorded from BON/VIAATGlyT2 cells were blocked with
strychnine (0.5 M, red bar; four superimposed ACh applications are shown with different colors).
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GlyT2 and 14.1  3.6 events/min (n  7)
for GlyT1, respectively; p  0.78; data not
shown].
Then we compared the capacity of the
two transporters to maintain a high [Gly]i,
and thus robust glycine exocytosis, in a
condition that promotes reverse trans-
port, as the two transporters differ in their
capacity to reverse direction (Roux and
Supplisson, 2000; Aubrey et al., 2005). In
this pulse-chase protocol, BON/VIAAT
cells expressing either GlyT1 or GlyT2
were cultured in nominally glycine-free
medium and exposed for 30 min to 30 M
glycine 14 –20 h before analysis with a
HEK/GlyR cell. Although glycine release
was preserved in all BON/VIAATGlyT2
cells analyzed, the glycine release fre-
quency of BON/VIAATGlyT1 cells was
markedly decreased by 62% (Fig. 3C–D).
This result suggests that in contrast to
GlyT2, when the extracellular glycine
concentration is limiting, GlyT1 cannot
maintain the high cytosolic glycine con-
centration required for its vesicular
accumulation.
Detection of glycine and GABA
vesicular corelease
To examine in our model whether com-
petition between GABA and glycine for
uptake by VIAAT can modify the vesicular
content, we coexpressed BON/VIAAT
GlyT2 cells with the plasmalemmal trans-
porter GAT1 and included GABA in the
BON culture medium (Fig. 4A). We were
able to differentiate clearly the release of each transmitter by co-
expressing in HEK cells GlyR and EXP-1A (EXP1), a C. elegans
GABA-gated receptor with cationic permeability (Beg and Jor-
gensen, 2003). When HEK/GlyREXP1 cells were held at 45
mV, fast application of glycine evoked an outward current,
whereas GABA evoked an inward current (Fig. 4B–C), but with a
different range of agonist sensitivity, as shown in the activation
curves of Figure 4D. Application of ACh triggered GABA release
from BON/VIAATGAT1 cells that evoked transient inward
currents in sniffer HEK/GlyREXP1 cells (Fig. 4E). Although
EXP-1 is insensitive to blockers of vertebrate GABA receptors,
such as bicuculline or picrotoxin (Beg and Jorgensen, 2003), we
are confident that these transient currents correspond to the ac-
tivation of EXP1 receptors by GABA release from BON cells as
they reversed near 0 mV (data not shown), the expected reversal
potential of EXP1 (Fig. 4C), and were never detected from
VIAAT-negative BON cells (data not shown). These individual
GABA events recorded with HEK/GlyREXP1 cells (Fig. 4E–F)
had slower kinetics (10 –90% rise time  33.0  1.1 ms and
10 –90% decay time  112  2.9 ms; n  659) than glycine events
(Fig. 4G). Nevertheless, their bimodal amplitude distribution
and their release rate (11.6  3.0 events/min of ACh application,
n  41) were similar to those of glycine release, indicating that
GABA and glycine are released from the same vesicular pools
(Fig. 4H). In contrast to glycine, GABA release was detected from
BON/VIAAT cells incubated with GABA but not transfected
with GAT1, suggesting the existence of an endogenous GABA
transporter. In agreement with this conclusion, GABA release
was markedly reduced, from 17.6 to 1.4 events/min, when BON/
VIAAT cells (not transfected with GAT1) were incubated with
the GABA transporter inhibitor NNC-711 (2.5 M).
The distinct kinetics and opposite polarity of glycine and
GABA events predict that the corelease of both neurotransmitters
from a single vesicle should evoke a fast outward component
followed by a slower inward one, representing the algebraic sum
of individual glycine and GABA events (Fig. 5A). Indeed, biphasic
outward/inward currents were recorded with HEK/GlyREXP1
cells (Fig. 5B–C). These events had a constant time interval be-
tween the outward and inward peaks (33.7  1 ms; n  607
events) (Fig. 5D), and the outward component was suppressed by
strychnine (Fig. 5E), confirming that they represent unitary core-
lease of glycine and GABA rather than coincident exocytoses.
Glycine and GABA competition for vesicular loading
by VIAAT
We categorized unitary events as glycinergic, GABAergic, or
mixed, according to their shape, and compared their proportions
in conditions of increasing GABA competition. A 100% glycine
release phenotype was only detected when BON/VIAATGlyT2
cells were incubated in the absence of GABA (Fig. 6A). In the
presence of equal extracellular concentrations of GABA and gly-
cine, GABA uptake by the endogenous transporter of BON cells
was sufficient to decrease the frequency of pure glycine events to
56  10% and to induce the appearance of both mixed and pure
Figure 3. GlyT2 supports glycine release more efficiently than GlyT1. A, Representative glycine release events recorded with a
HEK/GlyR cell apposed to BON/VIAATGlyT2 or BON/VIAATGlyT1 cells incubated for 12–24 h in [Gly]e  3 M. The current
traces correspond to three successive ACh applications and are shown with different colors. B, The normalized cumulative distri-
bution of glycine-event peak amplitudes recorded from eight BON/VIAATGlyT2 cells (closed circles; 59 Ach applications, 871
events) or from eight BON/VIAATGlyT1 cells (open squares; 37 Ach applications, 272 events) incubated overnight in 3 M
glycine. The solid line corresponds to the fit of the data with the sum of two log-normal cumulative distribution functions (n1 
5.1, 1  3.13, 1  0.41, n2  9.6, 2  4.7, 2  1.0 for GlyT2; and n1  3.7, 1  3.5, 1  0.6, n2  4.1, 2  5.7,
2  1.37 for GlyT1). C, Representative glycine release events recorded with a BON/VIAAT cell expressing GlyT2 or GlyT1, as in A,
but after a pulse-chase glycine-loading protocol: after transfection, BON cells were maintained in nominally glycine-free media
and exposed to 30 M glycine for 30 min 14 –20 h before experiments. D, The normalized cumulative distribution of the glycine-
event peak amplitudes recorded from five BON/VIAATGlyT2 cells (closed circles; 45 Ach applications, 1257 events) or from seven
BON/VIAATGlyT1 cells (open squares; 25 Ach applications, 264 events) incubated as described in C. The solid line correspond to
the fit of the data with the sum of two log-normal cumulative distribution functions (n1  10.1, 1  3.35, 1  0.48, n2 
16.7, 2  4.9; 2  1.04 for GlyT2; and n1  1.4, 1  3.2, 1  0.29, n2  4.9, 2  4.3; 2  0.8 for GlyT1).
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GABA events (Fig. 6B). When intracellular GABA ([GABA]i) was
further enhanced by the expression of the plasma membrane
GABA transporter GAT1 (Guastella et al., 1990), pure glycine
events were only rarely observed (8  4%) and GABA events
dominated (Fig. 6C). Finally, in the absence of GlyT2, a pure
GABAergic phenotype was observed when the GABA uptake was
enhanced by GAT1 expression (Fig. 6D). The amplitude of the
outward current in the mixed events decreased when GABA up-
take was enhanced by GAT-1 expression, as shown in Figure
6B–C, indicating that GABA replaces glycine in vesicles (Fig. 6E).
Glycine transport is an ancestral property of the vesicular
transporter and a single point mutation confers selectivity for
glycine
To examine whether VIAAT has been adapted for glycine exocy-
tosis during evolution, we replaced it by an invertebrate ortholog,
the C. elegans transporter UNC-47 (McIntire et al., 1997). Sur-
prisingly, although genomic data indicate that glycinergic trans-
mission does not exist in nematodes (Bargmann, 1998), we de-
tected glycine release and mixed events in addition to GABA
release when HEK/GlyREXP1 cells were apposed to BON cells
expressing GlyT2 and UNC-47 (Fig. 7A). As a negative control,
we introduced into UNC-47 the G462R mutation which impairs
GABAergic transmission in C. elegans (McIntire et al., 1997). In
agreement with the “shrinker” phenotype of unc-47(n2409)
worms, the G462R mutation abolished GABA release in our sys-
tem but, unexpectedly, it spared glycine release (Fig. 7B–C), thus
implying that the vesicular transport of glycine and GABA were
differentially affected. This constitutes the first evidence that the
vesicular accumulation of glycine and GABA can be molecularly
separated.
Discussion
We investigated the mechanisms underlying the secretory gly-
cine/GABA vesicular phenotypes. In our BON model, consecu-
tive glycine uptake by GlyT2 and VIAAT is necessary and suffi-
cient for concentrating glycine into vesicles, in agreement with
conclusions drawn from the genetic knock-out of GlyT2 and
VIAAT in mice (Gomeza et al., 2003; Wojcik et al., 2006). We
found that GlyT2 achieves more robust glycine release than
Figure 4. Detection of GABA release from BON/VIAAT cells with HEK/GlyREXP1 cells. A, Schematic representation of the BON/HEK293 model for the codetection of GABA and glycine release.
B, Glycine and GABA (200 M) evoked currents with opposite polarity in HEK/GlyREXP1 cells held at45 mV. C, Current–voltage relationships for glycine (closed circles; 200 M) and GABA- (open
circles; 200 M) evoked currents in HEK/GlyREXP1 cells. Currents were normalized to their absolute amplitude at 45 mV. D, Concentration-response curves of GlyR (filled circles; EC50  63.9 
9.1 M; h  2.5  0.5; n  5) and EXP1 receptors (open circles; EC50  6.5  0.5 M; h  1.4  0.1; n  6) were fitted using the Hill equation. GlyR- and EXP1-receptor mediated currents
properties were identical when the receptors were expressed individually or in combination. E, Current trace recorded with a HEK/GlyREXP1 cell apposed to a BON/VIAATGAT1 cell incubated
overnight in the presence of GABA and glycine (300 M each). Application of Ach (100 M) evoked only inward currents. F, GABA events (n  17; average trace is shown in red) recorded during a
single acetylcholine application. G, Distribution probabilities of the 10 –90% rise time (left) and 10 –90% decay time of GABA events (n  659). The cumulative probability is shown in red. H,
Normalized cumulative distribution of the peak amplitude of GABA events (n  659). The solid line corresponds to the fit of the sum of two log-normal distributions (dashed lines) with the values
of n1  4.8, 1  2.61, 1  0.3 (red line) and n2  6.8, 2  3.42, 2  0.61 (blue line).
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GlyT1, probably because the inability of GlyT2 to operate in the
efflux mode protects the cytosolic pool of glycine from variations
in extracellular glycine. By introducing GABA competition for
VIAAT, we were able to recreate the complete repertoire of in-
hibitory secretory phenotypes. Finally, we demonstrate that the
vesicular GABA transporter from C. elegans also transports
glycine.
Sniffer detection of glycine quanta
In our model system, the BON and HEK cells are the cellular
equivalents of giant “presynaptic” and “postsynaptic” elements.
Both cells were cultured separately, transfected with transporters
and receptors, and brought together only at the time of the ex-
periment. Although this system lacks the differentiation and or-
ganization of a neuronal synapse, its modularity, homogeneity,
and release properties offer several advantages to dissect out the
mechanisms determining a neurotransmitter phenotype. For ex-
ample, BON cells do not have an active zone where vesicles are
docked and primed for release; instead, vesicles must diffuse to
the plasma membrane after intracellular Ca 2 elevation before
eventually being released (Huet et al., 2006). This weak stimulus-
secretion coupling between the cytoplasmic Ca 2 oscillations
triggered by ACh and the exocytotic machinery is reflected by the
long latency and the low frequencies of the events recorded here
and practically eliminates the possibility that a release event de-
tected by the activation of GlyR in the HEK cells corresponds to
the simultaneous fusion of independent vesicles. Therefore, exo-
cytotic events evoked homogenous “synaptic-like” monophasic
currents in HEK cells that can be considered as quanta of glycine
release. The detection of this sparse neurotransmitter release
from BON cells was aided by the large intercellular contact with
the whole-cell patch-clamped HEK cell.
The distribution of the glycine current amplitudes was skewed
and covered two log scales. This large variation could result from
Figure 5. Detection of glycine and GABA corelease from individual vesicles. A, Algebraic sum
of representative glycine and GABA events (left) predicts a biphasic unitary event (right) if
glycine and GABA are released simultaneously. B, A representative unitary mixed event re-
corded with HEK/GlyREXP1 cell during ACh stimulation of a BON/VIAATGlyT2 cell incu-
bated overnight in the presence of 300 M GABA and glycine, reflecting GABA and glycine
corelease from a single vesicle. C, Current trace with pure GABA and mixed events recorded
during a single ACh application to a BON/VIAATGlyT2 cell incubated overnight in the presence
of glycine and GABA. For clarity, the outward current amplitude scale was fixed at 300 pA. The
inset shows traces of four consecutive mixed events with different peak amplitudes for the
outward and inward currents. D, Histogram of the latency between the outward and inward
peak current of mixed events. The solid line represents the cumulative probability. E, The glycine
outward component of mixed events (top, insert) evoked during ACh application is blocked by
the addition of 1 M strychnine (bottom, insert), with no change in release rate.
Figure 6. GlyT2-mediated [Gly]i can compete effectively with GABA for uptake by VIAAT.
A–D, Left, Examples of five consecutive 2 s recordings of quantal release during a single ACh
application to BON/VIAATGlyT2 (A, B), BON/VIAATGlyT2GAT1 (C), and BON/
VIAATGAT1 (D) cells incubated in [Gly]e  300 M without GABA (A) or in [Gly]e  [GABA]e
 300 M (B–D). Glycine, mixed, and GABA events are indicated by yellow circles, orange
squares, and red circles, respectively. Right, Proportions of glycine, mixed, and GABA events for
679 (A), 660 (B), 625 (C), and 512 (D) events recorded from 9 to 15 BON cells per condition. The
number of glycine, mixed, and GABA events detected were 679, 0, 0 (A); 336, 212, 110 (B); 40,
58, 527 (C); and 0, 0, 512 (D), respectively, for the different conditions described above. E,
Cumulative distribution of the peak amplitude of the glycine component of mixed currents
recorded from BON/VIAAT cells expressing GlyT2 alone (closed circles; n  20 cells) (see Fig. 6 B)
or in combination with GAT1 (open circles; n  7 cells) (see Fig. 6C). The mean glycine compo-
nent of mixed events decreases from 153.8  14.2 pA (n  127) to 58.0  13.4 pA (n  26)
when GAT1 is expressed ( p  0.016; two-tailed Mann–Whitney test).
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differences in the amount of glycine released per quantum or
from heterogeneity in GlyR density at the HEK cell surface. In
spinal cord slices, a similar distribution of glycinergic miniature
IPSC amplitudes has been described in some ventral horn inter-
neurons, and this variation was attributed to differences in the
size of postsynaptic GlyR clusters (Oleskevich et al., 1999). How-
ever, in absence of the scaffolding protein gephyrin (Kirsch et al.,
1993), homomeric 1-GlyRs have a uniform, unclustered distri-
bution in transiently transfected HEK cells (Legendre et al., 2002)
with a density 60 receptors/m 2 (Gentet et al., 2000), a value
that is below that estimated for glycinergic synapses (Choquet
and Triller, 2003). Therefore, because the detection of glycine in
our system is not restricted by the sharp boundaries defined by
receptor clusters, the variation in current amplitude likely reflects
changes in vesicular glycine content, which should be propor-
tional to the size of vesicles, which are known to be heterogeneous
in BON cells (Parekh et al., 1994; Kim et al., 2001).
GABA and glycine competition for VIAAT-mediated
vesicular filling
We took advantage of the cationic permeability of EXP1, a GABA
receptor from C. elegans (Beg and Jorgensen, 2003), to create an
inhibitory transmitter detector that differentiates glycine and
GABA release by the direction of the evoked current (outward
and inward, respectively). We show that VIAAT-containing ves-
icles accumulate both glycine and GABA, thus confirming the
inference from a long series of biochemical, morphological, phys-
iological, and genetic studies (Christensen et al., 1990; Burger et
al., 1991; McIntire et al., 1997; Sagné et al., 1997; Chaudhry et al.,
1998; Dumoulin et al., 1999; Wojcik et al., 2006). The slower time
course of GABA events compared with glycine events can be
explained by the differences in EC50 and Hill coefficients of the
two receptors. Indeed, the dose–response curves of EXP1 and
GlyR show that at low concentration (10 M), GABA evokes a
current in the HEK cell, whereas glycine cannot (Fig. 4D). Thus,
as GABA and glycine diffused away from the release site, GABA
should activate receptors over a larger area and for a longer time
period than glycine. Our detection method was not sensitive
enough to estimate the relative content of GABA and glycine in
vesicles, and therefore our analysis was limited to the categoriza-
tion of secretory events based on their shape. Homogenous pat-
terns of events with pure GABA or pure glycine release were only
observed in the absence of the other amino acid in the cytosol
(Fig. 6A,D), as expected for a nonselective vesicular transporter.
When vesicles had access to both GABA and glycine, we exam-
ined whether glycine can significantly compete with GABA. This
is an open question because, on one hand, GABA permeates lipid
bilayers much more efficiently than glycine at physiological pH
(Hell et al., 1991) and, on the other hand, neosynthesized GABA
has a kinetic advantage over glycine for vesicular uptake because
of a functional coupling between VIAAT and the vesicle-bound
biosynthetic enzyme GAD65 (Jin et al., 2003). In our experi-
ments, we observed various patterns of secretory phenotypes,
generally composed of a minority of mixed events associated with
either pure glycine or pure GABA events (Fig. 6B,C). In contrast,
we never observed both pure GABA and pure glycine events in
the absence of mixed events, nor did we record only mixed events
in the absence of glycine or GABA events. This under-
representation of mixed events was not anticipated. It may cor-
respond to an under-detection of mixed vesicles caused by an
uneven distribution of EXP1 and GlyR (see Keller et al., 2001).
However, this hypothesis is unlikely because it predicts a variable
shape of the mixed events (see above). Alternatively, the under-
representation of mixed events could result from a preferential
loading of either GABA or glycine in individual vesicles from the
same cell, as observed during focal stimulation of a single inhib-
itory bouton (Katsurabayashi et al., 2004).
One potential mechanism for such vesicular heterogeneity
could be that the association of VIAAT to protein partners (for
instance, GAD65) confers a preference for either GABA or gly-
cine uptake. Although one vesicular transporter is thought to be
sufficient to load vesicles with neurotransmitter (Daniels et al.,
2006), a recent study showed that several copies of vesicular
transporter are present on a single vesicle (Takamori et al., 2006);
thus, each vesicle may have a heterogeneous population of VI-
AAT molecules, each one interacting with different GABA and/or
glycine preferring partners. Another possibility is that one of the
two transmitters leaks from vesicles by a VIAAT-independent
manner (for the permeability of lipid bilayers to GABA, see Hell
et al., 1991), thus resulting in a dependence of the GABA-to-
glycine ratio of the vesicle on the density of VIAAT molecules in
its membrane. Therefore, although the phenotype of inhibitory
transmission may be determined entirely postsynaptically by the
expression of specific receptors on the target cells (Dugué et al.,
2005), our data and results from focal stimulation of a single
nerve terminal (Katsurabayashi et al., 2004) suggest that in some
regions, this variation may have a presynaptic origin. In agree-
ment, the postnatal switch in neuronal phenotypes described in
several sensorimotor structures (Kotak et al., 1998; Gao et al.,
2001; Keller et al., 2001) is associated in the lateral superior olive
with a downregulation of GAD65 (Nabekura et al., 2004) and an
upregulation of GlyT2 at the terminal (Friauf et al., 1999).
Figure 7. The vesicular GABA transporter of C. elegans, UNC-47 accumulates glycine and the
mutation G462R confers glycine specificity. A, Current trace recorded with a HEK/GlyREXP1
cell apposed to a BON/UNC47GlyT2 cell during a single ACh application (top trace). Numbers
mark the GABA, mixed, and glycine events shown below (red circle, orange squares, and yellow
circles, respectively). B, In contrast, only pure glycinergic events are detected from BON/
UNC47(G462R)GlyT2 cells. C, Bar graph of the proportions of cumulative glycine, mixed, and
GABA events from five BON/UNC-47GlyT2 cells (777 events) and 14 BON/UNC-47(G462R)
cells (259 events). The number of glycine, mixed, and GABA events detected were 91, 220, 466
for the BON/UNC-47GlyT2 and 259, 0, 0 for the BON/UNC-47(G462R) cells.
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Evolutionary implications of the comparison between VIAAT
and UNC-47
We show that, although invertebrates are thought to lack glycin-
ergic synapses, vesicles containing UNC-47, the vesicular GABA
transporter of C. elegans, accumulate glycine in GlyT2-expressing
BON cells. In addition, despite the competition between GABA
and glycine, mutation of a conserved glycine to arginine in the
tenth transmembrane domain of UNC-47 was sufficient to abol-
ish GABA uptake while preserving glycine uptake. Therefore, the
binding sites or translocation pathways of GABA and glycine in
UNC-47 and VIAAT may only partially overlap.
From a phylogenic viewpoint, the ability of UNC-47 to replace
VIAAT and transport glycine in our experiments suggests that the
emergence of glycinergic nerve terminals in vertebrates may have
resulted from a change in cytosolic glycine availability without
significant tuning-up of VIAAT for glycine. This scenario would
favor GABA-and-glycine corelease, suggesting that corelease
might have played an early physiological role in the vertebrate
lineage by expanding the repertoire of inhibitory signaling (Jonas
et al., 1998; Russier et al., 2002) and/or by allowing a gradual shift
from one transmitter to another (Kotak et al., 1998; Nabekura et
al., 2004). In addition, as glycine has the ability to interact with
neighboring N-methyl-D-aspartate receptors (Johnson and As-
cher, 1987) by spillover from inhibitory synapses (Ahmadi et al.,
2003), glycine cosignaling may also uniquely contribute to the
refinement of developing inhibitory and excitatory networks
(Kim and Kandler, 2003).
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